Deferoxamine: Clinical Trials

28 trials of Deferoxamine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 7 unknown, 4 terminated, 2 recruiting. 28 Phase 2, 4 Phase 1, 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 228Completed 14, Unknown 7, Terminated 4, Recruiting 2, Not yet recruiting 1
Phase 14Unknown 4
Phase 34Completed 2, Not yet recruiting 1, Unknown 1

Follow Deferoxamine: new trials by email Literature Review of Deferoxamine trials Research Report on Deferoxamine

Trials (filtered) newest first · largest first

All 28 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Synergistic Minimally Invasive Surgery and Deferoxamine in ICH
Minimally Invasive surgery (MIS), Deferoxamine, Standard Medical Care (SMD) - Intracerebral Hemorrhage, ICH - Intracerebral Hemorrhage
Phase 2 / Phase 3Not yet recruitingUniversity of Illinois at Chicago2402026-03-012025-10-10
Early Screening and Treatment of Heart Complication in Sickle Cell Disease
Deferoxamine, Deferasirox, Deferiprone - Sickle Cell Disease
Phase 2RecruitingInova Health Care Services1002025-10-072026-09-09
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers
Deferoxamine, Placebo - Diabetic Foot Ulcer
Phase 2UnknownKarolinska University Hospital1742022-12-302022-05-26
Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial
Deferoxamine, placebo - Intracranial Aneurysm, Subarachnoid Hemorrhage
Phase 1 / Phase 2UnknownRadboud University Medical Center402022-12-022023-04-24
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer
Deferoxamine Plus Chemotherapy - Triple Negative Breast Cancer
Phase 2TerminatedSun Yat-sen University252022-03-212025-07-22
Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)
Deferoxamine, Placebo - Aneurysmal Subarachnoid Hemorrhage
Phase 2RecruitingAditya S. Pandey, MD1202022-03-202026-11-12
Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury
Deferoxamine, Normal saline - Acute Kidney Injury
Phase 2CompletedBrigham and Women's Hospital3202021-04-132026-10-06
Application of Desferal to Treat COVID-19
Deferoxamine - COVID-19
Phase 1 / Phase 2UnknownKermanshah University of Medical Sciences502020-04-012020-05-04
Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia
Omega 3, Nigella Sativa Oil, Hydroxyurea - Iron Overload, Oxidative Stress
Phase 2 / Phase 3CompletedBeni-Suef University3502019-11-012021-01-27
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes
desferal, Isotonic saline - Diabetes Mellitus, Type 1
Phase 2UnknownKarolinska University Hospital302017-01-012022-05-26
Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage
deferoxamine, Xingnaojing injection, Normal saline - Intracerebral Hemorrhage
Phase 1 / Phase 2UnknownCapital Medical University1802015-03-012015-05-18
Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial
Deferoxamine Mesylate, Placebo (for Deferoxamine Mesylate) - Intracerebral Hemorrhage
Phase 2CompletedBeth Israel Deaconess Medical Center2942014-10-012019-05-30
Amlodipine for Myocardial Iron in Thalassemia
Standard Chelation, Amlodipine - Thalassemia
Phase 2 / Phase 3CompletedAga Khan University202014-02-012017-06-29
High-Dose Deferoxamine in Intracerebral Hemorrhage
Deferoxamine, Normal saline - Intracerebral Hemorrhage
Phase 2TerminatedBeth Israel Deaconess Medical Center422013-03-182019-06-12
Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload
DFP (ferriprox) and deferasirox (ICL 670), DFP, DFO - Beta-thalassemia Major, Sickle Cell Disease
Phase 2 / Phase 3UnknownAin Shams University602012-02-012012-02-06
Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload
Deferasirox and Deferoxamine - Cardiac Iron Overload
Phase 2CompletedNovartis Pharmaceuticals602011-01-012021-07-26
Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload
Deferasirox, Deferoxamine (DFO) - Transfusion-dependent β-thalassemia Patients, Cardiac Iron Overload
Phase 2TerminatedNovartis Pharmaceuticals322011-01-012019-10-23
N-acetylcysteine Plus Deferoxamine for Patients With Hypotension
N-acetylcysteine and deferoxamine - Hypotension, Acute Renal Failure
Phase 2CompletedUniversidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude812009-03-012015-05-28
Thrombolysis and Deferoxamine in Middle Cerebral Artery Occlusion
Deferoxamine - Ischemic Stroke, Acute
Phase 2CompletedGermans Trias i Pujol Hospital622008-09-012022-08-08
Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both
Deferoxamine, Deferasirox - Thalassemia
Phase 1 / Phase 2UnknownWeill Medical College of Cornell University62008-08-012010-11-05

Showing 20 of 28. Sign in to see all of them.

Conditions studied

Iron Overload (9)  ·  Thalassemia (6)  ·  Anemia, Sickle Cell (4)  ·  Cerebral Hemorrhage (4)  ·  beta-Thalassemia (4)  ·  Hemochromatosis (3)  ·  Intracranial Hemorrhages (3)  ·  Acute Kidney Injury (2)  ·  Myelodysplastic Syndromes (2)  ·  Stroke (2)  ·  Subarachnoid Hemorrhage (2)  ·  Anemia (1)  ·  Anemia, Diamond-Blackfan (1)  ·  Anemia, Hemolytic (1)  ·  Anemia, Sideroblastic (1)

Sponsors

Novartis Pharmaceuticals (6)  ·  Beth Israel Deaconess Medical Center (2)  ·  Karolinska University Hospital (2)  ·  Aditya S. Pandey, MD (1)  ·  Aga Khan University (1)  ·  Ain Shams University (1)  ·  Beni-Suef University (1)  ·  Brigham and Women's Hospital (1)  ·  Capital Medical University (1)  ·  Carelon Research (1)  ·  Elliott Vichinsky (1)  ·  Germans Trias i Pujol Hospital (1)  ·  Inova Health Care Services (1)  ·  Kermanshah University of Medical Sciences (1)  ·  Lipomed (1)

Countries

United States (12)  ·  Canada (6)  ·  Egypt (4)  ·  China (3)  ·  Greece (2)  ·  Italy (2)  ·  Taiwan (2)  ·  Thailand (2)  ·  Turkey (Türkiye) (2)  ·  United Kingdom (2)  ·  Brazil (1)  ·  Cyprus (1)  ·  Iran (1)  ·  Lebanon (1)  ·  Netherlands (1)

Top investigators

Magdy Selim, MD, PhD (2)  ·  Aditya Pandey, MD (1)  ·  Ahmed F Mahmoud Hussein, MS.c (1)  ·  Amir Kiani, PhD (1)  ·  Babar Hasan (1)  ·  David E. Leaf, MD, MMSc (1)  ·  Elliot Vichinsky, MD (1)  ·  Elliott P, Vichinsky, MD (1)  ·  Ellis J. Neufeld, MD (1)  ·  Gursant S. Atwal, MD (1)  ·  Javed Iqbal, MBBS (1)  ·  Jeroen Boogaarts, M.D., Ph.D. (1)

Results publications

PMID 33236783, PMID 37975597, PMID 10051178, PMID 10669330, PMID 11886437, PMID 1406879, PMID 16787239, PMID 17233848, PMID 18369153, PMID 18552864, PMID 22045831, PMID 22187937, PMID 22547607, PMID 2265118, PMID 22875626, PMID 23151373, PMID 23943316, PMID 24385534, PMID 25076907, PMID 25291189, PMID 25345697, PMID 25492271, PMID 25600572, PMID 25934475, PMID 27745551, PMID 28583206, PMID 29619244, PMID 29719970, PMID 30898550, PMID 33758069, PMID 34439518, PMID 34789008, PMID 35306827, PMID 35676589, PMID 38689404, PMID 38979830, PMID 40399657, PMID 40418029, PMID 40789806, PMID 7811060, PMID 8067783, PMID 8554902, PMID 8665150, PMID 9633879

NIH funding

U01NS074425 (2), 2009 (1), R01DK125786 (1), U01HL065232 (1), U01HL065238 (1), U01HL065239 (1), U01HL065244 (1), U01HL065260 (1)